Literature DB >> 22762033

Quality of life and physicians' perception in myelodysplastic syndromes.

Esther Natalie Oliva, Carlo Finelli, Valeria Santini, Antonella Poloni, Vincenzo Liso, Daniela Cilloni, Stefana Impera, Adelmo Terenzi, Alessandro Levis, Agostino Cortelezzi, Riccardo Ghio, Pellegrino Musto, Gianpietro Semenzato, Cristina Clissa, Teresa Lunghi, Silvia Trappolini, Valentina Gaidano, Flavia Salvi, Gianluigi Reda, Oreste Villani, Gianni Binotto, Patrizia Cufari, Elena Cavalieri, Maria Antonietta Aloe Spiriti.   

Abstract

To detect factors associated with quality of life (QOL) of patients with myelodysplastic syndrome (MDS) and to compare the MDS patients' self-assessed QOL with that perceived by their physicians. In an observational, non-interventional, prospective, multicentre study, QOL was evaluated in 148 patients with newly diagnosed low- and intermediate-risk IPSS MDS. QOL measures (QOL-E v.2, LASA and EQ-5D) and patient-related candidate determinants of QOL were assessed for up to 18 months. Patients' QOL scores were compared with those obtained by appointed hematologists' assessment and with ECOG performance status (PS). Fatigue was not prevalent at diagnosis, though physical QOL and energy levels were low. Transfusion-dependent patients had worse QOL scores. In multivariate analysis, Hb levels and comorbidities were a major determinant of QOL. Physicians' perception of patients' well-being correlated with patients' QOL. Physicians underestimated the impact of disturbances on patients' QOL, mainly in the MDS-specific components. ECOG PS did not discriminate patients according to QOL status. In conclusion, the association of anemia with QOL is confirmed, while co-morbidities emerge as an independent predictor of QOL in MDS. Fatigue is not a major concern. ECOG PS is not a valuable surrogate of patient's QOL, thus highlighting that physician's judgment of patient's well-being must not substitute patient-reported outcomes. Appropriate questionnaires should be used to assess MDS patients' QOL in order to improve communication and therapeutic choice.

Entities:  

Keywords:  Myelodysplastic syndromes; anemia; comorbidities; patient-reported outcomes; quality of life; transfusion-dependence

Year:  2012        PMID: 22762033      PMCID: PMC3384400     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  32 in total

1.  On summary measures analysis of the linear mixed effects model for repeated measures when data are not missing completely at random.

Authors:  R J Little; T Raghunathan
Journal:  Stat Med       Date:  1999 Sep 15-30       Impact factor: 2.373

2.  Accounting for dropout bias using mixed-effects models.

Authors:  C H Mallinckrodt; W S Clark; S R David
Journal:  J Biopharm Stat       Date:  2001 Feb-May       Impact factor: 1.051

3.  Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Authors:  B D Cheson; J M Bennett; H Kantarjian; A Pinto; C A Schiffer; S D Nimer; B Löwenberg; M Beran; T M de Witte; R M Stone; M Mittelman; G F Sanz; P W Wijermans; S Gore; P L Greenberg
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

4.  Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.

Authors:  Pellegrino Musto; Oreste Villani; Maria Carmen Martorelli; Giuseppe Pietrantuono; Roberto Guariglia; Giovanna Mansueto; Fiorella D'Auria; Vitina Grieco; Gabriella Bianchino; Anna Sparano; Antonia Zonno; Rosa Lerose; Grazia Sanpaolo; Antonietta Falcone
Journal:  Leuk Res       Date:  2009-11-20       Impact factor: 3.156

5.  Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).

Authors:  Peter L Greenberg; Zhuoxin Sun; Kenneth B Miller; John M Bennett; Martin S Tallman; Gordon Dewald; Elisabeth Paietta; Richard van der Jagt; Jessie Houston; Mary L Thomas; David Cella; Jacob M Rowe
Journal:  Blood       Date:  2009-06-29       Impact factor: 22.113

Review 6.  The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer.

Authors:  A Viganò; M Dorgan; E Bruera; M E Suarez-Almazor
Journal:  Cancer       Date:  1999-07-01       Impact factor: 6.860

7.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

8.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

10.  Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Authors:  Sophie Park; Sophie Grabar; Charikleia Kelaidi; Odile Beyne-Rauzy; Françoise Picard; Valérie Bardet; Valérie Coiteux; Geneviève Leroux; Pascale Lepelley; Marie-Thérèse Daniel; Stéphane Cheze; Béatrice Mahé; Augustin Ferrant; Christophe Ravoet; Martine Escoffre-Barbe; Lionel Adès; Norbert Vey; Lina Aljassem; Aspasia Stamatoullas; Lionel Mannone; Hervé Dombret; Keith Bourgeois; Peter Greenberg; Pierre Fenaux; François Dreyfus
Journal:  Blood       Date:  2007-10-16       Impact factor: 22.113

View more
  20 in total

1.  Costs and quality of life in patients with myelodysplastic syndromes.

Authors:  Carlo Lucioni; Carlo Finelli; Silvio Mazzi; Esther N Oliva
Journal:  Am J Blood Res       Date:  2013-08-19

2.  Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Authors:  U Platzbecker; P Fenaux; L Adès; A Giagounidis; V Santini; A A van de Loosdrecht; D Bowen; T de Witte; G Garcia-Manero; E Hellström-Lindberg; U Germing; R Stauder; L Malcovati; Mikkael A Sekeres; David P Steensma; S Gloaguen
Journal:  Blood       Date:  2018-11-07       Impact factor: 22.113

Review 3.  The Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology.

Authors:  Hemant S Murthy; William A Wood
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 4.  Palliative and End-of-Life Care in Myelodysplastic Syndromes.

Authors:  Myles Nickolich; Areej El-Jawahri; Thomas W LeBlanc
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

Review 5.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

6.  Stanozolol for the treatment of anemic lower-risk myelodysplastic syndromes without del(5q) after failure of epoetin alfa: findings from a retrospective study.

Authors:  Wei-Ying Qu; Lin Zhao; Xv-Cheng Tan; Yi-Han Zhao
Journal:  Ann Hematol       Date:  2021-04-10       Impact factor: 3.673

7.  Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS?

Authors:  A El-Jawahri; H T Kim; D P Steensma; A M Cronin; R M Stone; C D Watts; Y-B Chen; C S Cutler; R J Soiffer; G A Abel
Journal:  Bone Marrow Transplant       Date:  2016-03-21       Impact factor: 5.483

8.  Provider Perceptions of Quality of Life, Neurocognition, Physical Well-being, and Psychosocial Health in Patients with Primary Immunodeficiency/Immune Dysregulation Conditions.

Authors:  Thomas F Michniacki; Kelly J Walkovich; Lauren E Merz; Julie Sturza; Roshini S Abraham
Journal:  J Clin Immunol       Date:  2019-10-26       Impact factor: 8.317

Review 9.  Incidence and Burden of the Myelodysplastic Syndromes.

Authors:  Christopher R Cogle
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

10.  Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion-dependent anemia and thrombocytopenia.

Authors:  Guillermo Garcia-Manero; Antonio Almeida; Aristoteles Giagounidis; Uwe Platzbecker; Regina Garcia; Maria Teresa Voso; Stephen R Larsen; David Valcarcel; Lewis R Silverman; Barry Skikne; Valeria Santini
Journal:  BMC Hematol       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.